Statements (50)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
chemical compound
|
| gptkbp:approves |
gptkb:FDA
|
| gptkbp:availability |
prescription only
|
| gptkbp:brand |
gptkb:Buphenyl
|
| gptkbp:chemicalFormula |
aromatic compound
C12H10 |
| gptkbp:clinicalTrials |
ongoing
as directed by physician chronic management follow prescribing information |
| gptkbp:composedOf |
chemical synthesis
|
| gptkbp:contraindication |
allergic reactions
hypersensitivity |
| gptkbp:dissolved |
soluble in organic solvents
|
| gptkbp:dosageForm |
500 mg
tablets |
| gptkbp:drugInterdiction |
true
none significant absorbed in gastrointestinal tract reduces blood ammonia levels urea cycle disorder treatment |
| gptkbp:endOfLife |
3 hours
|
| gptkbp:formulation |
tablet form
|
| gptkbp:hasPopulation |
adults and children
|
| gptkbp:healthcare |
take with food
|
| https://www.w3.org/2000/01/rdf-schema#label |
Buphenyl
|
| gptkbp:is_monitored_by |
ammonia levels
|
| gptkbp:isATypeOf |
503-74-2
|
| gptkbp:issuedBy |
oral medication
|
| gptkbp:lastProduced |
2013
|
| gptkbp:mandates |
hyperammonemia
|
| gptkbp:marketedAs |
Ucyclyd_Pharma
|
| gptkbp:nutritionalValue |
liver
|
| gptkbp:origin |
diphenylbutyric_acid
|
| gptkbp:packaging |
bottles
|
| gptkbp:relatedTo |
ammonia detoxification
|
| gptkbp:researchInterest |
published in medical journals
|
| gptkbp:route |
oral
|
| gptkbp:safetyFeatures |
generally well tolerated
not for use in children under 2 years |
| gptkbp:sideEffect |
fatigue
headache nausea vomiting diarrhea |
| gptkbp:storage |
store at room temperature
|
| gptkbp:triggerType |
reduces ammonia levels
|
| gptkbp:usedFor |
treatment of urea cycle disorders
|
| gptkbp:waterManagement |
urine
|
| gptkbp:weight |
170.23 g/mol
|